Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia

This retrospective study aimed to determine the effect of liraglutide on weight and HbA1c levels in patients with type 2 diabetes mellitus (T2DM) in Saudi Arabia. The present investigation was carried out at a medical facility located in the Kingdom of Saudi Arabia. A retrospective analysis was conducted on the clinical records of 290 patients who were diagnosed with T2DM and were above 18 years of age. These patients were administered liraglutide for a minimum of 6 months. The dataset comprised various parameters such as the duration of diabetes, duration of liraglutide therapy, weight, and multiple biochemical markers such as HbA1c and low-density lipoprotein cholesterol levels. These parameters were measured both before and after the administration of liraglutide therapy. The primary metrics evaluated in this study were alterations in body weight and levels of glycated hemoglobin (HbA1c). Over the 24-month observational period, significant reductions in body mass index (38.6 kg/m2 to 37 kg/m2), body weight (99.3 kg to 96 kg), and HbA1c levels (8.9% to 7.8%) (all P < 0.01) were seen. Liraglutide reduced HbA1c levels and weight and affected multiple metabolic markers in patients with T2DM in a real-world setting in Saudi Arabia.